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Abstract
Background: Overexpression of RRM1 and RRM2 has been associated with gemcitabine resistance. BRCA1 overexpression
increases sensitivity to paclitaxel and docetaxel. We have retrospectively examined the effect of RRM1, RRM2 and BRCA1
expression on outcome to gemcitabine plus docetaxel in advanced non-small-cell lung cancer (NSCLC) patients.
Methodology and Principal Findings: Tumor samples were collected from 102 chemotherapy-naı ¨ve advanced NSCLC
patients treated with gemcitabine plus docetaxel as part of a randomized trial. RRM1, RRM2 and BRCA1 mRNA levels were
assessed by quantitative PCR and correlated with response, time to progression and survival. As BRCA1 levels increased, the
probability of response increased (Odds Ratio [OR], 1.09: p=0.01) and the risk of progression decreased (hazard ratio [HR],
0.99; p=0.36). As RRM1 and RRM2 levels increased, the probability of response decreased (RRM1: OR, 0.97; p=0.82; RRM2:
OR, 0.94; p,0.0001) and the risk of progression increased (RRM1: HR, 1.02; p=0.001; RRM2: HR, 1.005; p=0.01). An
interaction observed between BRCA1 and RRM1 allowed patients to be classified in three risk groups according to
combinations of gene expression levels, with times to progression of 10.13, 4.17 and 2.30 months (p=0.001). Low BRCA1
expression was the only factor significantly associated with longer time to progression in 31 patients receiving cisplatin-
based second-line therapy.
Conclusions: The mRNA expression of BRCA1, RRM1 and RRM2 is potentially a useful tool for selecting NSCLC patients for
individualized chemotherapy and warrants further investigation in prospective studies.
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Introduction
Non-small-cell lung cancer (NSCLC) remains the leading cause
of cancer death[1], with little improvement in survival regardless
of the type of chemotherapy used, either in combination or as
single agents[2]. Combinations of third-generation cytotoxic
agents, such as taxanes, vinorelbine and gemcitabine, with
cisplatin have emerged as new standards. In several phase III
clinical trials in advanced NSCLC, the combination of platinum
with taxanes attained median survival times of 8–11 months and 1-
year survival of 31–46%[3]. Non-platinum-based combinations
with gemcitabine plus docetaxel or paclitaxel have yielded a
similar survival benefit with a more favorable toxicity profile[4,5].
In order to further improve survival, a phase III trial of customized
cisplatin according to ERCC1 mRNA levels in stage IV NSCLC
was carried out. Patients in the control arm received cisplatin plus
docetaxel, while in the genotypic arm, patients with low ERCC1
levels received cisplatin plus docetaxel and those with high levels
received gemcitabine plus docetaxel[6]. Although objective
response was higher in the genotypic arm than in the control
arm (50.7% vs 39.3%), this did not translate to improved survival.
The British Thoracic Oncology Group trial (BTOG1) also found
no association between ERCC1 levels and survival in advanced
NSCLC patients treated with docetaxel plus carboplatin[7].
Retrospective studies of stage IV NSCLC have reported that
patients with low ERCC1 or RRM1 mRNA levels had a median
survival up to 15 months when treated with gemcitabine plus
cisplatin, with more significant differences in survival according to
RRM1 levels[8,9,10]. A feasibility study of customized treatment
in NSCLC patients with high ERCC1 and low ribonucleotide
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gemcitabine plus docetaxel could be the optimal combination for
this subgroup of patients[11].
RRM1 and RRM2 are encoded by different genes on separate
chromosomes and their mRNAs are differentially expressed
throughout the cell cycle. Reduced expression of let-7 microRNA
(miRNA) is frequently observed in NSCLC[12] and often leads to
overexpression of RRM1 and RRM2[13]. Resistance to gemcita-
bine has been associated with both RRM1 and RRM2 overexpres-
sion[14,15]. Small interfering RNA targeting RRM2 enhanced
chemosensitivity to gemcitabine in pancreatic adenocarcinoma[16].
Inourstudyofmetastaticlung adenocarcinomapatientstreated with
gemcitabine plus docetaxel, patients with low levels of both RRM1
and RRM2 had a significantly higher response rate (60% vs 14.2%),
time to progression (9.9 vs 2.3 months), and overall survival (15.4 vs
3.6 months) than patients with high levels of both genes[17].
A close correlation has also been observed between expression
levels of RRM1 and BRCA1[18,19,20], and the loss of let-7 has
been shown to upregulate BRCA1 as well as RRM1 and
RRM2[13]. In addition, both BRCA1 and RRM1 are upregulated
in the SV40 T/t-antigen signature[21]. BRCA1 expression confers
differential chemosensitivity in cancer cell lines[22,23]. Ovarian
cancer patients in the lowest terciles of BRCA1 expression showed
sensitivity to cisplatin and resistance to paclitaxel and docetaxel,
while those in the highest terciles had resistance to cisplatin and
sensitivity to paclitaxel and docetaxel[23]. Low levels of BRCA1
also correlated with increased survival in NSCLC patients treated
with gemcitabine plus cisplatin[18].
In order to validate our previous findings on RRM1 and
RRM2[17] and to further investigate the role of BRCA1 in taxane
sensitivity and resistance, we retrospectively analyzed a series of
tumor samples from advanced NSCLC patients treated with
gemcitabine plus docetaxel in a randomized phase III trial carried
out by the Hellenic Oncology Research Group (HORG)[5].
Methods
Patients
Tumor samples were collected from primary tumors from
patients with histologically confirmed inoperable stage IIIB and IV
NSCLC, who were included in the experimental arm of a HORG
randomized trial carried out from April 1999 to September 2002
[5] (no trial registration required before 2005). Eligibility criteria
have been previously reported. The study was approved by the
Ethics Committees of the participating hospitals, and all patients
gave their signed informed consent prior to study entry. Patients
received first-line gemcitabine (GemzarH; Eli Lilly, Indianapolis,
IN, USA) 1000 mg/m
2 on days 1 and 8 and docetaxel (TaxotereH;
Sanofi-Aventis, Collegeville, NJ, USA) 100 mg/m
2 on day 8, with
human granulocyte colony-stimulating factor support every 3
weeks, as previously described. Patient evaluation was performed
at baseline and after every three cycles of chemotherapy[5].
Study design
The present study was a retrospective analysis of the prognostic
value of BRCA1, RRM1 and RRM2 mRNA expression in NSCLC
patients treated with first-line gemcitabine plus docetaxel. All
available tumor biopsies of the primary tumor with more than
100 cells per section were included in the analysis. All efficacy results
were assessed for all enrolled patients on an intent-to-treat basis.
Gene expression analysis
All paraffin-embedded tumors were reviewed by two indepen-
dent pathologists to define the most appropriate tumor area for
microdissection to ensure a minimum of 90% of tumor cells.
Malignant cells were procured using an Eppendorf piezoelectric
microdissector (Eppendorf, Hamburg, Germany). RNA was
purified by trizol LS method (Invitrogen, Carlsbad, CA, USA)
followed by isopropanol precipitation and DNase treatment
(Ambion, Austin, TX, USA). cDNA synthesis was performed
using SuperScript III reverse transcriptase (Invitrogen, Carlsbad,
CA, USA). Relative quantification of gene expression was
performed using the ABI Prism 7900HT Sequence Detection
System (Applied Biosystems, Foster City, CA, USA). (For further
details on the gene expression analysis, see Text S1).
Statistical analyses
Besides analyzing the expression levels of each gene as a
continuous variable, gene expression was also categorized in
terciles in order to explore the risk trend of the gene variables and
in order to easily identify groups of gene expression levels with
different risk. Responses were recorded according to the RECIST
criteria[24]. Median time to tumor progression and overall
survival were calculated from the start of treatment to the first
documented disease progression or death, respectively.
The potential association between baseline characteristics,
response and gene expression levels were compared with either
the two-sided Fisher’s exact test or the Chi-square test for
categorical variables and the Kruskal-Wallis test for continuous
variables. The normality of continuous variables was verified with
a Kolmogorov-Smirnov test. The Spearman test was used to
evaluate the correlation between BRCA1, RRM1 and RRM2
mRNA expression. All potential risk factors for response were
evaluated in a univariate analysis, and a multivariate logistic
regression analysis, with adjusted odd ratios and their 95%
confidence intervals (CI), was used to evaluate which of the factors
had a significant influence on response. The Hosmer-Lemeshow
likelihood test was used to assess the goodness of fit.
The association of risk factors with time-to-event endpoints was
analyzed with the log-rank test, and the Kaplan-Meier method
was used to plot the corresponding time-to-progression and
survival curves. A univariate Cox regression analysis, with hazard
ratios and 95% CIs, was used to assess the association between
each potential prognostic factor and survival and time to
progression. These factors were then included in a multivariate
Cox proportional hazards regression model with a stepwise
procedure (both forward and backward) to evaluate the indepen-
dent significance of different variables on survival and time to
progression. The likelihood ratio test was used to assess the
goodness of fit, and the Wald’s test was used to assess the
coefficient significance. In the case of potential multiple compar-
isons, the p-values were corrected with the Bonferroni correction.
All statistical calculations were performed with SPSS, version
15.0 (SPSS, Inc., Chicago, IL, USA). Two-sided p-values of less
than 0.05 were considered significant.
Results
Patient characteristics and clinical outcome
In the original randomized trial[5], 209 NSCLC patients were
treated with gemcitabine plus docetaxel; 107 were not included in
the present study due to lack of tumor tissue (Fig. 1). Clinical data
and samples from primary tumors were available for 102 patients,
who were included in the present study. Amplification of BRCA1,
RRM1 and RRM2 was successful in 96 samples. Eighty-one were
adenocarcinomas, ten squamous cell carcinomas, and five large-
cell carcinomas. Patient characteristics are shown in Table 1. In
the original trial, the response rate was 30%, time to progression 4
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patients assessed in the present study was similar: response rate
30.5%, time to progression 4.2 months, and median survival 10.5
months.
BRCA1, RRM1 and RRM2 mRNA expression levels
Median mRNA expression levels were 3.64 (range 0–34.37) for
BRCA1, 0.82 (range 0–325.23) for RRM1 and 27.16 (range 0.97–
256.84) for RRM2 (Table 1). Expression levels did not follow a
normal distribution (Fig. S1). There was no correlation between
age, gender, PS, or disease stage and BRCA1, RRM1 or RRM2
mRNA levels. Significant correlations were observed overall
between BRCA1 and RRM1 (r=0.27; p=0.008) and a non-
significant trend to correlation between RRM1 and RRM2
(r=0.19; p=0.06) mRNA levels. There was also a significant
inverse correlation between BRCA1 and RRM2 mRNA levels
(r=20.25; p=0.02). Table 1 also shows the mRNA expression
levels of the three genes according to terciles.
Gene expression and response to treatment
In order to predict response to treatment, a logistic regression
model was fitted for the expression of each gene as a continuous
variable. As BRCA1 levels increased, the probability of response
increased significantly (Odds Ratio [OR]=1.09; 95% CI, 1.02–
1.16; p=0.01). In contrast, as RRM2 levels increased, the
probability of response decreased significantly (OR=0.94; 95%
CI, 0.91–0.97; p,0.0001). A similar but non-significant trend was
observed for RRM1 levels (OR=0.97; 95% CI, 0.77–1.23;
p=0.82).
When responders were classified according to their gene
expression levels by terciles, the majority of responders had high
BRCA1 expression and low RRM2 expression: 58.6% in the
highest tercile of BRCA1 expression (p=0.002) and 72.4% in the
lowest tercile of RRM2 expression (p,0.0001) (Table 2).
The univariate logistic regression analysis revealed that low
RRM2 expression, ECOG PS 0, and high BRCA1 expression
were significantly associated with a higher probability of response
(Table 2). In the multivariate logistic regression analysis of these
variables together with RRM1 and disease stage, only low RRM2
expression emerged as an independent predictive factor for
response (Table 2).
Gene expression and time to progression
The univariate analysis for time to progression revealed that the
only clinical variable associated with time to progression was PS
(Hazard Ratio [HR] for PS 1–2, 1.55; 95% CI, 0.99–2.41;
p=0.05) (Table 3). The univariate analysis for time to progression
according to gene expression levels as continuous variables showed
Figure 1. Chart showing the process of obtaining archival
paraffin-embedded tumor biopsies for the assessment of
BRCA1, RRM1 and RRM2 mRNA expression. Two hundred and
nine patients were treated with gemcitabine plus docetaxel as part of a
phase III randomized trial in advanced NSCLC[5]. Tumor biopsy was
obtained from a total of 102 patients; 68 patients were ruled out
because only cytological specimens were available, and 39 bronchial
biopsies contained too few tumor cells for analysis. mRNA expression
analysis was feasible in tumor samples from 96 of 102 patients.
doi:10.1371/journal.pone.0003695.g001
Table 1. Patient characteristics.
N (%) Median (range)
Total patients 96 (100)
Gender
Male 87 (90)
Female 9 (10)
ECOG Performance Status
0 62 (65)
1 28 (29)
2 6 (6)
Stage
IIIB 25 (26)
IV 71 (74)
Age (years) 96 60 (37–76)
BRCA1 median value 96 3.64 (0–34.37)
BRCA1 by terciles (T)
BRCA1 T1 32 1.09 (0–2.31)
BRCA1 T2 32 3.64 (2.33–7.81)
BRCA1 T3 32 11.30 (8.07–34.37)
RRM1 median value 96 0.82 (0–325.23)
RRM1 by terciles (T)
RRM1 T1 32 0.26 (0–0.44)
RRM1 T2 32 0.82 (0.45–1.10)
RRM1 T3 32 2.18 (1.14–325.23)
RRM2 median value 96 27.16 (0.97–256.84)
RRM2 by terciles (T)
RRM2 T1 32 4.97 (0.97–13.93)
RRM2 T2 32 27.16 (15.04–45.71)
RRM2 T3 32 89.96 (46.08–265.84)
doi:10.1371/journal.pone.0003695.t001
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increased significantly: RRM1 (HR, 1.02; 95% CI, 1.01–1.02;
p=0.001); RRM2 (HR, 1.005; 95% CI, 1.001–1.008; p=0.01).
However, as BRCA1 levels increased, the risk of progression
decreased (HR, 0.99; 95% CI, 0.95–1.02; p=0.36).
When gene expression levels were categorized by terciles, the
risk of progression was greater for patients in the intermediate and
highest terciles of RRM1 and RRM2 than for those in the lowest
tercile: RRM1 intermediate tercile (HR, 1.20; 95% CI, 0.72–1.97;
p=0.49); RRM1 highest tercile (HR, 1.51; 95% CI, 0.91–2.51;
Table 2. Univariate and multivariate analyses for response to treatment.
CR+PR N (%) SD+PD N (%) p Univariate OR (95% CI) p Multivariate OR (95% CI) p
BRCA1 0.002
T1 8 (27.6) 23 (34.8) 0.31 (0.11–0.89) 0.03 0.54 (0.13–2.22) 0.40
T2 4 (13.8) 28 (42.4) 0.13 (0.04–0.44) 0.001 0.22 (0.05–1.01) 0.05
T3 17 (58.6) 15 (22.7) 1 1
RRM1 0.56
T1 12 (41.4) 20 (30.3) 1 1
T2 9 (31) 23 (34.8) 0.65 (0.23–1.87) 0.43 1.43 (0.34–6.03) 0.62
T3 8 (27.6) 23 (34.8) 0.58 (0.20–1.70) 0.32 0.95 (0.22–4.13) 0.94
RRM2 ,0.001
T1 21 (72.4) 10 (15.2) 1 1
T2 7 (24.1) 25 (37.9) 0.13 (0.04–0.41) ,0.001 0.20 (0.06–0.73) 0.02
T3 1 (3.4) 31 (47) 0.02 (0.002–0.13) ,0.001 0.02 (0.002–0.17) ,0.001
ECOG PS 0.02
0 24 (82.8) 38 (57.6) 1 1
1–2 5 (17.2) 28 (42.4) 0.28 (0.10–0.83) 0.02 0.44 (0.11–1.69) 0.23
STAGE 0.31
IIIB 10 (34.5) 15 (22.7) 1 1
IV 19 (65.5) 51 (77.3) 0.56 (0.21–1.46) 0.23 0.45 (0.12–1.74) 0.25
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; OR, odds ratio; T, terciles; PS, performance status.
doi:10.1371/journal.pone.0003695.t002
Table 3. Median time to progression according to gene expression, ECOG PS and disease stage.
TTP mos (95% CI) Log-rank p Univariate HR (95% CI) Cox p Multivariate HR (95% CI) Cox p
BRCA1 0.25
T1 3 (1.9–4.1) 1.51 (0.91–2.49) 0.11 1.51 (0.86–2.65) 0.15
T2 3.6 (2.2–4.9) 1.33 (0.80–2.22) 0.28 1.10 (0.62–1.95) 0.74
T3 5.5 (3.1–7.9) 1 1
RRM1 0.27
T1 6 (0.2–11.8) 1 1
T2 3.7 (0.6–6.6) 1.20 (0.72–1.97) 0.49 1.39 (0.82–2.37) 0.22
T3 3.3 (2.2–4.4) 1.51 (0.91–2.51) 0.11 1.72 (0.99–3) 0.06
RRM2 0.03
T1 8.7 (4.9–12.4) 1 1
T2 3.6 (2–5.2) 1.28 (0.77–2.13) 0.35 1.02 (0.57–1.80) 0.95
T3 2.7 (1.6–3.8) 1.93 (1.16–3.22) 0.01 1.55 (0.89–2.71) 0.12
PS 0.05
0 5.23 (3.99–6.48) 1 1
1–2 2.70 (1.99–3.41) 1.55 (0.99–2.41) 0.05 1.62 (1.01–2.59) 0.05
STAGE 0.13
IIIB 5.50 (1.86–9.15) 1 1
IV 4.17 (3.05–5.28) 1.45 (0.89–2.36) 0.13 1.43 (0.86–2.38) 0.17
TTP, time to progression; HR, hazard ratio; T, tercile; PS, performance status.
doi:10.1371/journal.pone.0003695.t003
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2.13; p=0.35); RRM2 highest tercile (HR, 1.93; 95% CI, 1.16–
3.22; p=0.01) (Table 3). The risk of progression was greater for
patients in the intermediate and lowest tercile of BRCA1 than for
those in the highest tercile: BRCA1 intermediate tercile (HR, 1.33;
95% CI, 0.80–2.22; p=0.28); BRCA1 lowest tercile (HR, 1.51;
95% CI, 0.91–2.49; p=0.11) (Table 3). Time to progression
according to gene expression by terciles is shown in Table 3.
A multivariate model was fitted with the variables examined in
the univariate setting.
When interaction terms were examined to check whether they
significantly improved the fit, none was significant except for
BRCA*RRM1, which gave a significance of p=0.02 to the model
without the interaction term (Table S1). The multivariate model
was then stratified by RRM1 (Table S2) and without disease stage.
In this model, patients in the lowest tercile of RRM2 continued to
have the lowest risk of progression, independently of RRM1 levels.
Patients were classified in three groups according to risk of
progression, based on the interaction observed between RRM1 and
BRCA1. Twenty-four patients were in the low-risk group (interme-
diate BRCA1+low RRM1; high BRCA1+low RRM1; high
BRCA1+intermediate RRM1); 42 patients were in the intermedi-
ate-riskgroup(lowBRCA1+low RRM1;intermediate BRCA1+high
RRM1; high BRCA1+high RRM1); and 30 patients were in the
high-risk group (low BRCA1+intermediate RRM1; intermediate
BRCA1+intermediate RRM1; low BRCA1+high RRM1).
The median time to progression was 10.13 months (95% CI,
7.65–12.62) for patients in the low-risk group, 4.17 months (95%
CI, 72.90–5.44) for patients in the intermediate-risk group, and
2.30 months (95% CI, 1.76–2.84) for patients in the high-risk
group (p=0.001) (Tables S2, S3; Fig. 2).
Gene expression and survival
In the univariate analysis of survival, the only significant clinical
variable was PS (HR for PS 1–2, 1.94; 95% CI, 1.21–3.12;
p=0.005) (Table 4). As RRM1 and RRM2 values increased, the
risk of death increased: RRM1 (HR, 1.01; 95% CI, 1.00–1.02;
p=0.005); RRM2 (HR, 1.004; 95% CI, 1.00–1.008; p=0.06).
However, as BRCA1 levels increased, the risk of death decreased
(HR, 0.99; 95% CI, 0.96–1.03; p=0.60). When gene expression
levels were categorized in terciles, the same pattern of increased
risk of death was observed for higher levels of both RRM1 and
RRM2 and lower levels of BRCA1 (Table 4). In the multivariate
model including all the variables from the univariate analysis, only
PS emerged as a significant factor for survival (Table 4).
Gene expression and second-line treatment
Second-line therapy was administered in 31 patients, 90.3% of
whom received cisplatin-based chemotherapy. There were no
differences in gene expression levels between patients receiving
and those not receiving second-line therapy. Time to progression
for all 31 patients calculated from the start of second-line therapy
was 3.40 months (95% CI, 2.73–4.07). In contrast to the pattern
observed with first-line therapy, low levels of BRCA1 were
significantly associated with the lowest risk of progression to
second-line therapy. Median time to progression was 6.60 months
for patients in the lowest tercile, 2 months for those in the
intermediate tercile, and 2.40 months for those in the highest
tercile of BRCA1 expression (p=0.004) (Table 5, Fig. 3). BRCA1
mRNA expression emerged as the only significant factor in both
the univariate and multivariate analyses of time to progression in
the 31 patients receiving second-line therapy (Table 6).
Discussion
The present study has found an inverse correlation between
RRM2 mRNA expression and response to gemcitabine plus
docetaxel in advanced NSCLC patients. Patients with low RRM2
mRNA expression attained a significantly higher response rate and
time to progression than those with high RRM2 expression. In
addition, RRM2 mRNA expression was revealed as an indepen-
dent predictive factor for response. These results confirm our
earlier findings in a small cohort of lung adenocarcinomas treated
with the same regimen[17]. Although median RRM2 levels were
different in the two studies, possibly due to slight differences in
patient populations or in some steps of the RNA extraction and
PCR quantification procedures, the correlation between mRNA
levels and clinical results was similar in both studies. Intriguingly,
transgenic mice developed lung adenocarcinoma but not other
tumors in the presence of RRM2 overexpression[25]. In earlier
retrospective studies[8,9], we found that high levels of RRM1
predicted longer survival in stage IV NSCLC patients treated with
gemcitabine plus cisplatin but not in those treated with cisplatin-
based regimens without gemcitabine.
The significant correlation between the top tercile of BRCA1
mRNA expression and improved response observed in the present
study adds to the growing body of evidence that BRCA1 is a
crucial mediator of DNA damage response[26]. Low BRCA1
expression confers increased sensitivity to cisplatin[22,23,27,28]
and etoposide[22] and resistance to antimicrotubule drugs, such as
Figure 2. Time to progression according to risk groups. Patients
were classified in three groups according to risk of progression, based
on the interaction observed between RRM1 and BRCA1. Twenty-four
patients were in the low-risk group (intermediate BRCA1+low RRM1;
high BRCA1+low RRM1; high BRCA1+intermediate RRM1); 42 patients
were in the intermediate-risk group (low BRCA1+low RRM1; interme-
diate BRCA1+high RRM1; high BRCA1+high RRM1); and 30 patients
were in the high-risk group (low BRCA1+intermediate RRM1; interme-
diate BRCA1+intermediate RRM1; low BRCA1+high RRM1). The median
time to progression was 10.13 months (95% CI, 7.65–12.62) for patients
in the low-risk group, 4.17 months (95% CI, 72.90–5.44) for patients in
the intermediate-risk group, and 2.30 months (95% CI, 1.76–2.84) for
patients in the high-risk group (p=0.001) (See also Tables S2, S3).
doi:10.1371/journal.pone.0003695.g002
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BRCA1 expression leads to resistance to cisplatin[22,23,27,28] and
etoposide[22] and sensitivity to paclitaxel[22,23,28], docetaxel[23]
and vinorelbine[22]. In the present study, patients with low BRCA1
mRNA expression had poor response and time to progression to
first-line gemcitabine plus docetaxel; in contrast, they obtained the
maximum benefit from second-line cisplatin-based treatment,
attaining a median time to progression of 6.6 months.
Several layers of evidence show that the abrogation of BRCA1
function leads to resistance to antimicrotubule drugs. Spindle
Table 4. Median survival according to gene expression, PS and disease stage.
MS mos (95% CI) Log-rank p Univariate HR (95% CI) Cox p Multivariate HR (95% CI) Cox p
BRCA1 0.37
T1 12 (6.4–17.6) 1.28 (0.74–2.21) 0.37 1.39 (0.75–2.56) 0.29
T2 8.5 (2.2–14.8) 1.51 (0.85–2.88) 0.16 1.48 (0.79–2.79) 0.22
T3 12.7 (5.7–19.7) 1 1
RRM1 0.39
T1 12 (5.7–18.3) 1 1
T2 10.6 (5.3–15.8) 1.17 (0.68–2.02) 0.57 1.37 (0.76–2.46) 0.29
T3 11.2 (2.9–19.5) 1.47 (0.85–2.56) 0.17 1.73 (0.94–3.18) 0.08
RRM2 0.48
T1 15.2 (10.1–20.2) 1 1
T2 9.3 (3.7–14.8) 1.15 (0.66–2.01) 0.62 0.74 (0.39–1.40) 0.35
T3 6.6 (1.5–11.7) 1.40 (0.81–2.42) 0.23 0.91 (0.49–1.71) 0.77
PS 0.005
0 15.17 (10.15–20.18) 1 1
1–2 6.30 (4.16–8.44) 1.94 (1.21–3.12) 0.006 2.07 (1.25–3.43) 0.005
STAGE 0.10
IIIB 17.93 (2.25–33.62) 1 1
IV 10.27 (5.85–14.68) 1.57 (0.92–2.63) 0.10 1.45 (0.85–2.47) 0.18
MS, median survival; HR, hazard ratio; T, tercile; PS, performance status.
doi:10.1371/journal.pone.0003695.t004
Table 5. Time to progression after first-line treatment
according to gene expression levels in 31 patients receiving
second-line therapy.
N TTP mos (95% CI) p
BRCA1 0.004
T1 16 6.60 (6.42–6.78)
T2 10 2.00 (0.92–3.09)
T3 5 2.40 (2.19–2.62)
RRM1 0.49
T1 10 2.60 (1.67–3.53)
T2 13 5.80 (1.64–9.96)
T3 8 3.50 (2.67–4.33)
RRM2 0.76
T1 5 6.50 (0.11–12.90)
T2 9 5.80 (0–12.23)
T3 17 3 (1.92–4.08)
TTP, time to progression; T, tercile.
doi:10.1371/journal.pone.0003695.t005
Figure 3. Time to progression after first-line treatment
according to BRCA1 terciles. In contrast to the pattern observed
with first-line therapy, low levels of BRCA1 were significantly associated
with the lowest risk of progression to second-line therapy. Median time
to progression was 6.60 months for patients in the lowest tercile, 2
months for those in the intermediate tercile, and 2.40 months for those
in the highest tercile of BRCA1 expression (p=0.004) (Table 5). (For
further details, see text.)
doi:10.1371/journal.pone.0003695.g003
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vinca alkaloids. Suppression of Mad2 or BubR1 in paclitaxel-
treated breast cancer MCF-7 cells abolishes spindle checkpoint
function, resulting in enhanced paclitaxel resistance[29]. In
addition, downregulation of BRCA1 expression mediates pacli-
taxel resistance through premature inactivation of spindle
checkpoint in MCF-7 cells via downregulation of BubR1[30].
BRCA1 dysfunction is closely related to spindle checkpoint defects
but not to G2 phase alterations. Indeed, a set of gene expression
alterations due to the knockdown of endogenous BRCA1 has been
identified in prostate (DU-145) and breast (MCF-7) cancer cells by
DNA microarray analysis[31]. Various categories of genes are
downregulated in BRCA1-knockdown cells, including genes in-
volved in transcription and cell cycle regulation and in DNA
replication and repair. BRCA1-short interference RNAs (siRNAs)
also caused the downregulation of DNA topoisomerase II alpha
(TOP2A), an enzyme involved in DNA replication and in both the
DNA damage-responsive G2 checkpoint and the G2 decatenation
checkpoint. This checkpoint requires TOP2A, ATR, WRN
(Werner’s syndrome helicase), and BRCA1; it is defective in cells
with mutant BRCA1. However, in contrast to BRCA1-mutant cell
lines, knockdown of wild-type BRCA1 did not attenuate this
checkpoint but showed attenuation of the mitotic spindle check-
point[31]. BRCA1 positively regulates the expression of many genes
involved in the spindle checkpoint, such as Bub1 and BubR1.
Consistent with these findings, cells pretreated with BRCA1-siRNAs
failed to arrest in metaphase after treatment with nocodazole[31].
Interestingly, BRCA1-siRNAs also caused downregulation of
metabolism genes, including RRM2 and dihydrofolate reductase
(DHFR)[31]. Moreover, an integrated gene signature from
multiple transgenic models of epithelial cancers intrinsic to the
functions of the Simian virus 40T/t-antigens is composed of genes
regulating cell replication, proliferation and DNA repair. BRCA1
is overexpressed in three T/t-antigenic transgenic mouse models
(breast, lung, prostate), as are other genes, including Bub1b,
TOP2A, DHFR, thymidylate synthase (TS), and RRM1[21].
The limited efficacy of current chemotherapy approaches is
epitomized in metastatic NSCLC, where time to progression ranges
from 5.2 to 5.5 months, with different combinations of chemother-
apy, such as docetaxel plus cisplatin[32] or new compounds like
pemetrexed (an inhibitor of TS and DHFR) plus cisplatin[33].
Therefore, in spite of the retrospective nature of the present study, a
time to progression of 10 months in 24 of 96 patients in the low-risk
group (high BRCA1 and low RRM1 levels), treated with docetaxel
plus gemcitabine, represents a promising new landmark that merits
validation in a prospective trial of customized chemotherapy. These
clinical findings are similar to those obtained with EGFR tyrosine
kinase inhibitors in NSCLC patients harboring EGFR mutations. In
the only prospective study reported of treatment with gefitinib in 31
NSCLC patients with EGFR mutations, a time to progression of 9.2
months was attained[34].
Fromthe present study,we cannot determine whetherthe mRNA
expression of BRCA1, RRM1 or RRM2 could have a prognostic –
as well as a predictive – role. In early-stage, chemonaive, resected
NSCLC patients, BRCA1 mRNA expression was the only
independent prognostic variable[20]. Similarly, high mRNA
expression of the BRCA1-interacting protein BACH1/Brip1 has
been found in aggressive breast cancers[35]. In addition, BRCC36
has been shown to be present in the BRCA1-RAP80 complex
[36]and is overexpressed in breast cancer, where it confers
radioresistance[37]. This highlights the possibility that BRCA1 –
or several interacting partners – can confer poor prognosis as well as
resistance to cisplatin or other DNA-damaging agents.
In summary, our findings indicate that the efficacy of
gemcitabine plus docetaxel can be improved when customized
according to the mRNA expression of BRCA1, RRM1 and
RRM2. It is intriguing to speculate that BRCA1 could become an
important predictive marker for customizing pemetrexed plus
cisplatin in patients with low BRCA1 levels, since BRCA1 could
be a surrogate of DHFR and TS levels[21,31]. Prospective studies
of customized chemotherapy based on the expression of these
genes have been opened.
Table 6. Univariate and multivariate analyses of time to progression after first-line therapy for 31 patients receiving second-line
treatment.
N Univariate HR (95% CI) Cox p Multivariate HR (95% CI) Cox p
BRCA1
T1 16 1 1
T2 10 3.35 (1.33–8.44) 0.01 4.37 (1.53–12.49) 0.006
T3 5 4.78 (1.50–15.26) 0.008 6.61 (1.86–23.50) 0.004
RRM1
T1 10 1 1
T2 13 0.76 (0.32–1.85) 0.55 0.47 (0.14–1.60) 0.23
T3 8 0.54 (0.19–1.53) 0.24 0.37 (0.10–1.35) 0.13
RRM2
T1 51 1
T2 9 0.72 (0.21–2.49) 0.61 1.22 (0.24–6.14) 0.81
T3 17 1.01 (0.32–3.10) 0.99 1.82 (0.42–8.01) 0.43
PS
0 22 1 1
1–2 9 1.61 (0.67–3.83) 0.28 1.78 (0.64–4.91) 0.27
HR, hazard ratio; PS, performance status.
doi:10.1371/journal.pone.0003695.t006
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